Sofía Castelli

PhD Candidate @Penn | @carlhjune lab | MSc @DrexelUniv | @FulbrightPrgrm Scholar 2018 | Pharmaceutical Chemist @Udelaruy @FqUdelar

[Sofía Castelli @msofiacastelli]

Excited to see our work come to life!

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

📘Finally came! With our chapter on Adoptive Cellular Therapies, including table tracking ways to enhance #TCell potency. 1000X thanks to coauthors @lococyte @msofiacastelli @giugolli @carlhjune #celltherapy #genetherapy #immunotherapy https://t.co/k9YcKeOIpv

[ACIR @ACIR_org]

Fueling CAR with IL-9 https://t.co/VDtRYGeLiZ  @msofiacastelli

[David Usharauli @3DiMMUNE]

IL-9, the little-known cytokine, finally found its calling, helping CAR T cells take on solid tumors. More staying power, more memory, more punch.

#science
#immunology

https://t.co/8cFuepwufy

[Cell Therapy News @celltherapynews]

New in @ImmunityCP: @msofiacastelli and a team in the @carlhjune lab engineered CAR T cells with IL-9 signaling to boost efficacy against #SolidTumors.

https://t.co/6rngTEqAUW

[John Connolly @John_E_Connolly]

IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy: Immunity ⁦@parkerici⁩ ⁦@PennMedicine⁩ https://t.co/A9YoZanH8p

[Sofía Castelli @msofiacastelli]

@PennMedicine @PennMedCSO

[Sofía Castelli @msofiacastelli]

Check out our paper out today in Immunity!

Paper link: https://t.co/cno9YnaZ84

This work is the result of my PhD project in Dr. Carl June’s lab, and I’m incredibly proud to finally see it published.

[Sofía Castelli @msofiacastelli]

This work highlights a promising strategy to improve CAR T therapies for solid cancers through IL-9 signaling.

Grateful to my mentors, Carl June and Gina Young, as well as the rest of the authors for making this possible!

[Eric Topol @EricTopol]

Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP
https://t.co/brwOZIgZOU
https://t.co/QfMQRIYWo6

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Report of note: IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy
•Engineering CAR T cells with IL-9 signaling boosts efficacy against solid tumors
•IL-9-signaling CD4+ CAR T cells have increased Th1 and proliferative phenotypes
•Single-cell profiling reveals that IL-9 redirects CD8+ T cell fate away from dysfunction
•IL-9-induced STAT1/STAT4 activation contributes to improved CAR T cell function https://t.co/ShNOmkCeQC

[Immunity @ImmunityCP]

Online now: IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy https://t.co/WfM00JODhA

[Waggoner Lab @LabWaggoner]

IL-9 enhancement of engineered CAR-T therapies
@ImmunityCP @carlhjune @msofiacastelli
@Penn @xrtcell @stanford @KaylaKulhanek
https://t.co/sR5kYp6bFg
https://t.co/krqVAgKU38

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

🚨Coming soon! Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. In a single lentiviral vector- multiplex silencing & expression of a CAR, better expansion & viability than gene editing by electroporation @PennMedicine https://t.co/SgxNiljpxm @FrontiersIn https://t.co/fMfore499X

[Penn Medicine CSO @PennMedCSO]

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients with B-cell lymphoma who had exhausted other treatment options ft. @carlhjune (@PennPathLabMed) & Jakub Svoboda (@PennCancer) @UPenn_I3H https://t.co/HN9ub9jzx6

[Penn Medicine Cancer @PennCancer]

Congratulations to our own Drs. June and Levine!

[Penn Medicine Cancer @PennCancer]

Penn researchers found that next-generation IL18-armored #CARTCellTherapy shows promise for patients whose #lymphoma resisted multiple other cancer treatments, including commercial CAR T cell therapies. @carlhjune @NEJM @AACR #NCRM #UnitedByCancerResearch https://t.co/COyxS3uwYo

[Parker Institute for Cancer Immunotherapy @parkerici]

CAR T-cell therapy isn’t just a breakthrough—it’s a lifeline. A new PICI-supported review in @MolTherapy by @carlhjune, Director of the PICI Center at @PennMedicine, and team traces the decades of research that made engineered immune cells a powerful cancer treatment. https://t.co/8MQuGAUZYX

[Parker Institute for Cancer Immunotherapy @parkerici]

CAR T-cell therapy has transformed treatment for 35K+ patients, with a well-established safety profile. New in @TheLancet: @carlhjune, Director of the PICI Center at @PennMedicine, @BLLPHD & @daniel_baker_j explore latest data and what’s next in the field. https://t.co/V0CdDpG6k1

[AACR @AACR]

Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: https://t.co/rTTAK8h6zk @parkerici @PennMedicine

[Sofía Castelli @msofiacastelli]

@Yo19940376 @carlhjune Thank you!!

[Sofía Castelli @msofiacastelli]

Excited to share my PhD thesis work with @CarlHJune now out as a preprint on bioRxiv! We show that engineering IL-9 signaling enhances CAR T cell antitumor efficacy by steering them toward potent memory and effector states.
https://t.co/DY32T5dAiT